Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy
Joint Authors
Topkan, Erkan
Selek, Ugur
Mertsoylu, Huseyin
Kucuk, Ahmet
Besen, Ali Ayberk
Sezer, Ahmet
Sezen, Duygu
Bolukbasi, Yasemin
Pehlivan, Berrin
Source
Gastroenterology Research and Practice
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-07-30
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Background.
We investigated the prognostic significance of pretreatment systemic inflammation response index (SIRI) in locally advanced pancreatic carcinoma (LAPC) patients treated with concurrent chemoradiotherapy (CRT).
Methods.
Present retrospective cohort analysis investigated consecutive 154 LAPC patients who received radical CRT.
The SIRI was defined as: SIRI=neutrophil×monocyte/lymphocyte counts.
Ideal SIRI cutoff(s) influencing overall survival (OS) and progression-free survival (PFS) results were sought by using receiver operating characteristic (ROC) curve analysis.
The primary endpoint was the interaction between the SIRI and OS results.
Results.
The median follow-up, PFS, and OS durations were 14.3 (range: 2.9-74.6), 7.9 [%95 confidence interval (CI): 5.7-10.1), and 14.7 months (%95 CI: 11.4-18.0) for the entire cohort, respectively.
ROC curve analyses determined the ideal SIRI cutoff that exhibiting a significant link with OS and PFS outcomes at the rounded 1.6 point (AUC: 74.3%; sensitivity: 73.8%; specificity: 70.1%).The SIRI <1.6 patients (N=58) had significantly superior median PFS (13.8 versus 6.7 months; P<0.001) and OS (28.6 versus 12.6 months; P<0.001) lengths than SIRI ≥1.6 patients (N=96), respectively.
Although the N0 (versus N1; P<0.05) and CA 19-9 ≤90 U/mL (versus >90 U/mL) appeared as the other significant associates of better OS and PFS in univariate analyses, yet the results of multivariate analyses confirmed the SIRI <1.6 as the independent indicator of superior OS and PFS (P<0.001 for each).
Conclusion.
Pretreatment SIRI is a novel independent prognosticator that may further enhance the conventional tumor-node-metastases staging system in a more precise prediction of the OS and PFS outcomes of LAPC patients after radical CRT.
American Psychological Association (APA)
Topkan, Erkan& Mertsoylu, Huseyin& Kucuk, Ahmet& Besen, Ali Ayberk& Sezer, Ahmet& Sezen, Duygu…[et al.]. 2020. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterology Research and Practice،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1166888
Modern Language Association (MLA)
Topkan, Erkan…[et al.]. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterology Research and Practice No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1166888
American Medical Association (AMA)
Topkan, Erkan& Mertsoylu, Huseyin& Kucuk, Ahmet& Besen, Ali Ayberk& Sezer, Ahmet& Sezen, Duygu…[et al.]. Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. Gastroenterology Research and Practice. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1166888
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1166888